The Journal of Experimental Medicine · 1995 · 185 citations · 29 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesCell-based ImmunotherapyMajor Histocompatibility ComplexT Cell Responses To TumorsCd8 Positive T CellsCd8 T Cell ActivationClass Ii Histocompatibility AntigensImmunogenicity Of Tumor AntigensMhc Class Ii MoleculesTumor ImmunogenicityTumor-specific T Cell ActivationVectored Vaccines
Mice carrying large established major histocompatibility complex (MHC) class 1+ sarcoma tumors can be successfully treated by immunization with genetically engineered sarcoma cells transfected with syngeneic MHC class II plus B7-1 genes. This approach is significantly more effective than previously described strategies using cytokine- or B7-transduced tumor cells which are only effective against smaller tumor loads, and which cannot mediate regression of longer-term established tumors. The most efficient tumor rejection occurs if both the class II and B7-1 molecules are coexpressed on the same tumor cell. Immunity induced by immunization with class II+B7-1(+)-transfected sarcoma cells involves CD4+ and CD8+ T cells, suggesting that the increased effectiveness of the transfectants is due to their ability to activate both of these T cell populations.
29
Glen Dranoff, Elizabeth M. Jaffee, A Lazenby et al. · Proceedings of the National Academy of Sciences · 1993 · 2.8K citations
Medicine, Immunology, Oncology +17
Lieping Chen, Stephanie Ashe, William Brady et al. · Cell · 1992 · 1.1K citations
Life Sciences, Immunology, Oncology +16
Properties of Monoclonal Antibodies to Mouse Ig Allotypes, H-2, and Ia Antigens
Vernon T. Oi, Pauline Jones, James W. Goding et al. · 1979 · 979 citations
M Sarmiento, Andrew L. Glasebrook, Frank W. Fitch · The Journal of Immunology · 1980 · 817 citations